1
|
Barthelemy P, Thibault C, Voog E, Eymard JC, Ravaud A, Flechon A, Abraham Jaillon C, Hilgers W, Le Moulec S, Chasseray M, Pouessel D, Amela Y, Lorgis V, Nicolas E, Kazan E, Denechere G, Solbes MN, Lambert P, Loriot Y. 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F. Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer. Cancer Radiother 2022; 26:670-677. [PMID: 35260342 DOI: 10.1016/j.canrad.2021.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 11/24/2021] [Accepted: 12/12/2021] [Indexed: 12/24/2022]
Abstract
PURPOSE Roughly 20% of patients with non-small-cell lung cancer exhibit locally advanced, unresectable, stage III disease. Concurrent platinum-based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet with poor long-term prognosis. This phase II trial (IFCT-0803) sought to evaluate whether adding cetuximab to cisplatin and pemetrexed chemoradiotherapy would improve its efficacy in these patients. MATERIALS AND METHODS Eligible patients received weekly cetuximab (loading dose 400mg/m2 day 1; subsequent weekly 250mg/m2 doses until two weeks postradiotherapy). Chemotherapy comprised cisplatin (75mg/m2) and pemetrexed (500mg/m2), both delivered on day 1 of a 21-day cycle of maximally four. Irradiation with maximally 66Gy started on day 22. Disease control rate at week 16 was the primary endpoint. RESULTS One hundred and six patients were included (99 eligible patients). Compliance exceeded 95% for day 1 of chemotherapy cycles 1 to 4, with 76% patients receiving the 12 planned cetuximab doses. Maximal grade 3 toxicity occurred in 63% patients, and maximal grade 4 in 9.6%. The primary endpoint involving the first 95 eligible patients comprised two (2.1%) complete responses, 57 (60.0%) partial responses, and 27 (28.4%) stable diseases. This 90.5% disease control rate (95% confidence interval [95% CI]: 84.6%-96.4%) was achieved at week 16. After median 63.0-month follow-up, one-year and two-year survival rates were 75.8% and 59.5%. Median overall survival was 35.8months (95% CI: 23.5-NR), and median progression-free survival 14.4months (95% CI: 11.2-18.8), with one-year and two-year progression-free survival rates of 57.6% and 34.3%. CONCLUSION These survival rates compare favourably with published data, thus justifying further development of cetuximab-based induction chemoradiotherapy.
Collapse
Affiliation(s)
- J Trédaniel
- Department of pneumology, hôpital Saint-Joseph, 75014 Paris, France.
| | - F Barlési
- Multidisciplinary oncology and therapeutic innovations department, centre hospitalier universitaire de Marseille, 13000 Marseille, France
| | - C Le Péchoux
- Department of radiation oncology, Gustave-Roussy, 94805 Villejuif, France
| | - D Lerouge
- Department of radiation oncology, centre François-Baclesse, 14000 Caen, France
| | - É Pichon
- Department of pneumology, centre hospitalier universitaire de Tours, 37000 Tours, France
| | - S Le Moulec
- Department of pneumology, institut Bergonié, 33000 Bordeaux, France
| | - L Moreau
- Department of pneumology, hôpital Louis-Pasteur, 68024 Colmar, France
| | - S Friard
- Department of pneumology, hôpital Foch, 92150 Suresnes, France
| | - V Westeel
- Department of pneumology, centre hospitalier universitaire de Besançon, 25000 Besançon, France
| | - L Petit
- Department of pneumology, centre hospitalier Alpes Léman, 74130 Contamine-sur-Arve, France
| | - O Carré
- Department of pneumology, clinique de l'Europe, 80090 Amiens, France
| | - F Guichard
- Department of oncology, polyclinique, 33000 Bordeaux, France
| | - O Raffy
- Department of pneumology, hôpital de Chartres, 28000 Chartres, France
| | - J Villa
- Department of pneumology, centre hospitalier universitaire de Grenoble, 38000 Grenoble, France
| | - A Prévost
- Department of pneumology, centre de lutte contre le cancer Jean-Godinot, 51100 Reims, France
| | - A Langlais
- Intergroupe francophone de cancérologie thoracique, 75000 Paris, France
| | - F Morin
- Intergroupe francophone de cancérologie thoracique, 75000 Paris, France
| | - M Wislez
- Department of pneumology, hôpital Cochin, 75014 Paris, France
| | - P Giraud
- Department of radiation Oncology, hôpital européen Georges-Pompidou, 75015 Paris, France
| | - G Zalcman
- Department of pneumology, centre hospitalier universitaire de Caen, 14000 Caen, France
| | - F Mornex
- Department of radiation oncology, centre hospitalier universitaire de Lyon, 69000 Lyon, France
| | | |
Collapse
|
3
|
Thurin N, Rouyer M, Gross-Goupil M, Soulié M, Roumiguié M, Le Moulec S, Capone C, Chevalier J, Lamarque S, Bignon E, Jové J, Droz-Perroteau C, Moore N, Blin P. Validation d’un algorithme complexe dans le Système national des données de santé. Exemple avec le cancer de la prostate résistant à la castration et métastatique. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
4
|
Cho B, Reinmuth N, Lee K, Ahn MJ, Luft A, Van den Heuvel M, Dols MC, Smolin A, Vicente D, Moiseyenko V, Antonia S, Moulec SL, Robinet G, Natale R, Garon E, Nakagawa K, Liu F, Thiyagarajah P, Peters S, Rizvi N. Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
5
|
Leroy L, Lafarge X, Blouin L, Bijou F, Durrieu F, Olivier E, Le Moulec S. A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor. Ann Oncol 2019; 29:514-515. [PMID: 29088313 DOI: 10.1093/annonc/mdx693] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- L Leroy
- Medical Oncology Department, Bergonie Institute, Bordeaux, France
| | - X Lafarge
- Inserm Unit 1035, EFS, Bordeaux, France
| | - L Blouin
- Inserm Unit 1035, EFS, Bordeaux, France
| | - F Bijou
- Department of Medical Hematology, Bergonie Institute, Bordeaux, France
| | - F Durrieu
- Department of Biology Hematology, Bergonie Institute, Bordeaux, France
| | - E Olivier
- Department of Cell Biology, Albert Einstein College of Medicine, Bronx, USA
| | - S Le Moulec
- Medical Oncology Department, Bergonie Institute, Bordeaux, France.
| |
Collapse
|
6
|
Rizvi N, Chul Cho B, Reinmuth N, Lee K, Ahn MJ, Luft A, van den Heuvel M, Cobo M, Smolin A, Vicente D, Moiseyenko V, Antonia S, Le Moulec S, Robinet G, Natale R, Nakagawa K, Zhao L, Stockman P, Chand V, Peters S. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy511.005] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Hendriks L, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier Valette C, Mazieres J, Lefebvre C, Le Moulec S, Duchemann B, Le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Planchard D, De Ruysscher D, Dingemans AM, Besse B. Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Ferrara R, Caramella C, Texier M, Audigier-Valette C, Tessonnier L, Mezquita L, Lahmar J, Mazieres J, Zalcman G, Brosseau S, Westeel V, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Champiat S, Fertè C, Planchard D, Boucher M, Martinez-Bernal G, Bria E, Tortora G, Soria J, Besse B. MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Oudard S, Mejean A, Topart D, Thuret R, Tournigand C, Salomon L, Thiery-Vuillemin A, Guichard G, Le Moulec S, Houlgatte A, Guillot A, Mottet N, Cessot A, Barry-Delongchamps N, Elaidi R, Turajlic S, Swanton C, Escudier B, Patard J, Albiges L. Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Leroy L, Massé J, Adam J, Brouste V, Signolle N, Soubeyran I, Velasco V, Khalifa E, Lortal B, Italiano A, Besse B, Le Moulec S. IDO-1 and PD-L1 predict response to immunotherapy in advanced non small cell lung cancer: An NGS and multiplex IHC analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Gataa I, Mezquita L, Auclin E, Le Moulec S, Alemany P, Kossai M, Massé J, CARAMELLA C, Remon Masip J, Lahmar J, Ferrara R, Gazzah A, Soria JC, Planchard D, Besse B, Adam J. Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Ferrara R, Caramella C, Texier M, Audigier Valette C, Tessonnier L, Mezquita L, Lahmar J, Mazieres J, Zalcman G, Brosseau S, Westeel V, Le Moulec S, Leroy L, Duchemann B, Veillon R, Planchard D, Boucher ME, Koscielny S, Soria JC, Besse B. Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 2016; 16:168. [PMID: 26923772 PMCID: PMC4770547 DOI: 10.1186/s12885-016-2192-6] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Accepted: 02/17/2016] [Indexed: 02/05/2023] Open
Abstract
Background High circulating tumor cell (CTC) counts are associated with poor prognosis in advanced prostate cancer, and recently CTC number was suggested to be a surrogate for survival in metastatic castrate-resistant prostate cancer (mCRPC). Ki67 and vimentin are well-characterised markers of tumour cell proliferation and the epithelial-mesenchymal transition (EMT), respectively. Here we asked if the expression of vimentin and Ki67 in CTCs offered prognostic or predictive information in mCRPC. Methods In two separate patient cohorts, anti-vimentin or anti-Ki67 antibodies were added to the free channel in the CellSearch® system for analysis of peripheral blood samples. For each cohort, association of CTC number with clinical characteristics were assessed using Fisher’s exact, Mann-Whitney and chi-squared tests. Kaplan-Meier method and log-rank tests were used to analyse overall survival (OS) of vimentin-expressing and Ki67-expressing CTC patient cohorts. Results In this retrospective analysis, CTC vimentin expression was analysed in 142 blood samples from 93 patients, and CTC Ki67 expression was analysed in 90 blood samples from 51 patients. In the vimentin cohort, 80/93 (86 %) of baseline samples from patients were CTC-positive overall (≥1 total CTC per 7.5 mls blood), and 30/93 (32.3 %) vimentin CTC-positive (≥1 vimentin-positive CTC per 7.5 mls blood). 41/51 (80.4 %) of baseline samples from patients in the Ki67 cohort were CTC-positive overall, and 23/51 (45.1 %) Ki67 CTC-positive (≥1 Ki67-positive CTC per 7.5 mls blood). There was no significant difference in baseline PSA in patients with vimentin-positive CTC at baseline versus those with no vimentin-positive CTC at baseline (p = 0.33). A significant reduction in OS was shown in patients with vimentin-positive CTC compared to those without vimentin-positive CTC (median 305 days vs 453 days, p = 0.0293). There was no significant difference in baseline PSA in patients with Ki67-positive CTC at baseline versus those without Ki67-positive CTC (p = 0.228), but OS was significantly reduced in the Ki67-positive CTC group (median 512 days vs 751 days, p = 0.0091). No changes in relative proportion of vimentin- or Ki67-positive CTCs were observed in post-treatment samples compared to baseline. Conclusions Analysis of vimentin and Ki67 expression can straightforwardly be assessed in CTCs from patients with mCRPC. Poorer survival outcomes were observed in vimentin- and Ki67-positive CTC patients. Translational study protocols CEC-CTC (IDRCB2008-AOO585-50) and Petrus (NCT01786031). Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2192-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- C R Lindsay
- INSERM U981, University of Paris-Sud XI, Translational Research Laboratory, Gustave Roussy Cancer Campus, Villejuif, France.
| | - S Le Moulec
- Department of Medical Oncology, Bergonie Cancer Institute, Bordeaux, France.
| | - F Billiot
- INSERM U981, University of Paris-Sud XI, Translational Research Laboratory, Gustave Roussy Cancer Campus, Villejuif, France.
| | - Y Loriot
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
| | - M Ngo-Camus
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
| | - P Vielh
- INSERM U981, University of Paris-Sud XI, Translational Research Laboratory, Gustave Roussy Cancer Campus, Villejuif, France. .,Department of Biopathology, Gustave Roussy Cancer Campus, Villejuif, France.
| | - K Fizazi
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
| | - C Massard
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
| | - F Farace
- INSERM U981, University of Paris-Sud XI, Translational Research Laboratory, Gustave Roussy Cancer Campus, Villejuif, France.
| |
Collapse
|
14
|
Angelergues A, Bellmunt J, Efstathiou E, Gonzalez I, Gyftaki R, Delanoy N, Ozguroglu M, Flechon A, Guillot A, Le Moulec S, Castellano D, Esteban E, Munarriz J, Campos Balea B, Ardavanis A, Stefanou D, Oudard S. 2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31357-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Oudard S, Angelergues A, Efstathiou E, Gonzalez I, Gyftaki R, Delanoy N, Ozguroglu M, Flechon A, Guillot A, Le Moulec S, Castellano D, Esteban E, Munarriz J, Campos Balea B, Ardavanis A, Stefanou D, Bellmunt J. 2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31360-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Gervais R, Molinier O, Chouaid C, Barlesi F, Denis F, Berard H, Corre R, Dansin E, Lecaer H, Moro-Sibilot D, Rebattu P, Burki F, Khayat D, Le Moulec S, Pérol M, Pouessel D, Robinet G, Nanda S, Depenbrock H, Socinski MA, Thatcher N. SQUIRE : étude multicentrique randomisée de phase III, en ouvert, évaluant gemcitabine-cisplatine (GC) plus necitumumab versus GC en première ligne de traitement du CBNPC épidermoïde (épi) de stade IV. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Oudard S, Angelergues A, Maeso IG, Delanoy N, Flechon A, Özgüroğlu M, Castellano D, Guillot A, Le Moulec S, Esteban E, Munarriz J, Campos B, Bellmunt J. Prognostic Factors for Survival and Sequencing of Life-Extending Therapies in Metastatic Castration Resistant Prostate Cancer (Mcrpc) Patients (Pts) in Post-Docetaxel (D) Setting. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.37] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Miller K, Hussain M, Le Moulec S, Rybicka I, Bruns R, Straub J. Abituzumab (Di17E6, Emd 525797) Treatment for Chemotherapy-Naive Patients with Asymptomatic or Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Primary Outcomes of the Placebo-Controlled Phase 2 Study Perseus (Nct01360840). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Moussaid Y, Bertaux M, Chargari C, Helissey C, Le Moulec S, Errihani H, Vedrine L. Fièvre et cancer : éléments de diagnostic pour une prise en charge adaptée. Rev Med Interne 2013. [PMID: 23199412 DOI: 10.1016/j.revmed.2012.10.368] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Y Moussaid
- Service d'oncologie et radiothérapie, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75230 Paris cedex 05, France.
| | | | | | | | | | | | | |
Collapse
|
20
|
Jacob J, Chargari C, Helissey C, Ferrand FR, Ceccaldi B, Le Moulec S, Bauduceau O, Fayolle M, Védrine L. [Neuroendocrine carcinoma of the digestive tract: a literature review]. Rev Med Interne 2013; 34:700-5. [PMID: 23871177 DOI: 10.1016/j.revmed.2013.02.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2011] [Revised: 06/12/2012] [Accepted: 02/08/2013] [Indexed: 01/10/2023]
Abstract
Neuroendocrine carcinoma is a rare and agressive malignant tumor, mainly developing at the expense of the respiratory and of the digestive tract. Among the digestive tract, appendix, small bowel, and pancreas are the preferential sites of involvement, other locations have been more rarely reported. Neuroendocrine digestive tumors may present with various symptoms in relationship with their localization and a complex pathophysiology. Diagnosis is often made at an advanced stage, explaining partly the bad prognosis of these tumors. The optimal management of digestive neuroendocrine tumors is rendered difficult by their rarity and by a low number of randomized trials. We review the literature regarding epidemiologic and prognostic features of these rare tumors, their diagnostic and therapeutic care. Potential complications are also discussed.
Collapse
Affiliation(s)
- J Jacob
- Service d'oncologie-radiothérapie, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Chargari C, Moussaid Y, Helissey C, Jacob J, Bauduceau O, Ceccaldi B, Védrine L, Le Moulec S. Pemetrexed and Whole-Brain Radiation Therapy for Treatment of Brain Metastases from Non Small-Cell Lung Adenocarcinoma: A Single Instituton Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32993-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
22
|
Yassine M, Védrine L, Chargari C, Ceccaldi B, Le Moulec S, Ichou M, Errihani H. Sexuality of Breast Cancer Patients Treated with Mastectomy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34021-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
23
|
Albiges L, Le Moulec S, Loriot Y, Gross Goupil M, De La Motte Rouge T, Guillot A, Fizazi K, Massard C. Reponse to Cabazitaxel in the Postchemotherapy Setting in Crpc Patients Previously Treated with Docetaxel and Abiraterone Acetate. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33512-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
24
|
Albiges L, Riet F, Massard C, Le Moulec S, Loriot Y, Levy A, Fizazi K, Escudier B. Second Line Treatment in Metastatic Papillary Renal Cell Carcinoma: Retrospective Analysis of a 48 Patients Cohort. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33408-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
25
|
Besse B, Le Moulec S, Senellart H, Mazieres J, Barlesi F, Dansin E, Robinot G, Perol M, Moro-Sibilot D, Soria J. Phase II Study of Bevacizumab in Combination with 1st-Line Chemotherapy or 2nd-Line Erlotinib in Non-Squamous Nsclc (Ns-Nsclc) Patients with Asymptomatic Untreated Brain Metastases (ML21823). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33897-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
26
|
Helissey C, Védrine L, Ceccaldi B, Houlgatte A, Mullot H, Bauduceau O, Chargari C, Massard C, Fizazi K, Moulec SL. Continuous Infusion Bleomycin in the Bep Regimen: A Therapeutic Alternative in the Management of Patients with Germ-Cell Tumors? Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33435-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
27
|
Loriot Y, Houédé N, Le Moulec S, Hennequin C, Eymard J, Beuzeboc P, Oudard S, Culine S, Carrasco AT, Fizazi K. 7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72002-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Kedzeriewicz R, Chargari C, Le Moulec S, Jacques Ferrandes N, Houlgatte A, Vedrine L. Knowledge of testicular cancer and screening acceptance: Results from a prospective study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
231 Background: A delayed diagnosis of testicular cancer is associated with both greater morbidity and poorer prognosis. We conducted a prospective study in the French Armed Forces to assess whether a short medical education could increase the degree of acceptance of the routine clinical screening for testicular cancer. Methods: We enrolled 415 consecutive military patients aged 18-45 years and consulting their army general practitioner. The degree of knowledge on the testicular cancer was assessed using a self-questionnaire, which also served as short medical education. We compared the degree of acceptance for testicular palpation before and after the education delivery. Results: Only 26.8% of patients (n = 107) assumed that they had previously received general information on testicular cancer and 31 patients (7.8%) reported that they were informed on the risk factors of testicular cancer (CI95: 5.5-10.8). In the population, 16.3% of patients (n = 65) had been informed on the usefulness of self-palpation of testes. Wilcoxon tests show significant differences between baseline acceptance level before any intervention and after information delivery (p<0.000001). In details, acceptance of testicular palpation after responding the questionnaire did not change in 82.25%, increased in 15%, and decreased in 2.75%. Conclusions: Young males in military environment are poorly aware of testicular cancer, but there is a demand on medical education regarding this disease. The time of annual medical visit for aptitude is probably the optimal time for this education. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Kedzeriewicz
- Val-de-Grace Hospital, Paris, France; Brigade des Sapeurs Pompiers, Paris, France
| | - C. Chargari
- Val-de-Grace Hospital, Paris, France; Brigade des Sapeurs Pompiers, Paris, France
| | - S. Le Moulec
- Val-de-Grace Hospital, Paris, France; Brigade des Sapeurs Pompiers, Paris, France
| | - N. Jacques Ferrandes
- Val-de-Grace Hospital, Paris, France; Brigade des Sapeurs Pompiers, Paris, France
| | - A. Houlgatte
- Val-de-Grace Hospital, Paris, France; Brigade des Sapeurs Pompiers, Paris, France
| | - L. Vedrine
- Val-de-Grace Hospital, Paris, France; Brigade des Sapeurs Pompiers, Paris, France
| |
Collapse
|
29
|
Abstract
Nausea and vomiting are frequent symptoms that deteriorate the quality of life of lung cancer patients. They are most often iatrogenic and related to chemotherapy based on platinum salts; they can also be evidence of metastasis to the brain or hypercalcemia. Understanding the physiopathological mechanisms at work can make it possible to adopt effective therapeutic measures that are specific to each etiological context.
Collapse
Affiliation(s)
- S Le Moulec
- Service d'Oncologie, Hôpital du Val-de-Grâce, 74 Boulevard de Port-Royal, 75005 Paris, France.
| | | |
Collapse
|
30
|
Védrine L, Chargari C, Le Moulec S, Fayolle M, Ceccaldi B, Bauduceau O. [Cancer chemotherapy of the upper aerodigestive tract]. Cancer Radiother 2008; 12:110-9. [PMID: 18187355 DOI: 10.1016/j.canrad.2007.11.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2007] [Revised: 11/22/2007] [Accepted: 11/23/2007] [Indexed: 11/29/2022]
Abstract
Tumours of the upper aerodigestive tract represent the sixth most frequent kind of cancer in France and throughout the world. If the localised forms may be controlled in the long run in two thirds of cases by surgery or radiotherapy, only one third of locally advanced forms are accessible to a cure after association from radiotherapy and chemotherapy. Besides, with a median of survival less than six months, metastatic tumours present a catastrophic spontaneous prognosis among patients with a medical ground that is often heavily deteriorated by prolonged exposure to alcohol and tobacco. Thus, there is a necessity to implement adapted therapeutic strategies to each patient and based on satisfactory proof levels of effectiveness. Optimisation of existing chemotherapy protocols and development of new therapies, in particular of targeted therapies, remain an important objective in the hope to improve results of treatments in locally advanced and metastatic cancers of the oral cavity.
Collapse
Affiliation(s)
- L Védrine
- Service d'oncologie et radiothérapie, hôpital d'instruction des Armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France
| | | | | | | | | | | |
Collapse
|
31
|
Bonnichon A, Vedrine L, Aletti M, Le Moulec S, Borne M, Margery J, Bauduceau O, Fayolle M, Ceccaldi B. [Favorable outcome of gemcitabine-induced acute respiratory distress syndrome]. Rev Pneumol Clin 2007; 63:379-383. [PMID: 18166944 DOI: 10.1016/s0761-8417(07)78425-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Gemcitabine is a new important drug used to treat solid tumors including non-small cell lung cancer, pancreatic, bladder and breast cancers. Myelosuppression is the most common adverse effect. Pulmonary toxicity is rare and usually mild and self-limiting with acute dyspnea. Severe pneumonitis and potentially fatal acute respiratory distress syndrome (ARDS) have been described in patients treated for a non-small cell lung cancer. We report a case of gemcitabine-induced ARDS in a 72-year old patient treated with gemcitabine and cisplatin for a bladder cancer without lung metastasis. Administration of high doses of corticosteroids led to a prompt symptomatic improvement.
Collapse
Affiliation(s)
- A Bonnichon
- Service des Maladies Respiratoires, Hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92140 Clamart.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Margery J, Le Moulec S, Olaru I, Ruffie P. 227 Métastase cérébrale chez des patients porteurs d’un mésothéliome pleural malin : à propos de 3 observations. Rev Mal Respir 2007. [DOI: 10.1016/s0761-8425(07)72603-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Védrine L, Bauduceau O, Fayolle M, Le Moulec S, Ceccaldi B. Intérêt de la chimiothérapie néoadjuvante dans le traitement des séminomes purs intracérébraux : expérience de l'hôpital du Val-de-Grâce. Cancer Radiother 2005; 9:335-40. [PMID: 16019248 DOI: 10.1016/j.canrad.2005.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2004] [Revised: 06/10/2005] [Accepted: 06/22/2005] [Indexed: 11/30/2022]
Abstract
Optimal management of intracranial germinomas remains controversial. Focal irradiation to the primary tumor followed by prophylactic craniospinal radiotherapy represents the traditional treatment resulting in excellent long-term survival but potential late effects. To decrease late effects related to extensive fields of radiotherapy, combined chemotherapy and irradiation has been tested with reduced volumes and doses of radiation therapy. We report our experience about four patients successfully treated by neoadjuvant chemotherapy with carboplatin and etoposide followed by radiotherapy delivering 26 to 36 Gy to the whole brain and 36 to 50 Gy to the initial tumor volume.
Collapse
Affiliation(s)
- L Védrine
- Service d'oncologie médicale et radiothérapie, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75230 Paris cedex 05, France.
| | | | | | | | | |
Collapse
|
34
|
Abstract
Thoracoscopy-talc led to the diagnosis of epithelial pleural mesothelioma in a 58-year-old man who presented with pleurisy. The course was rapidly unfavorable despite systemic chemotherapy. Dorsal pain revealed invasion of the spine and spinal canal leading to cord compression three months after the diagnosis of mesothelioma.
Collapse
Affiliation(s)
- J Margery
- Service de Médecine, Institut Gustave-Roussy, Villejuif, France.
| | | | | | | |
Collapse
|
35
|
Margery J, Le Moulec S, Grassin F, Guigay J, Vaylet F, L'her P. [Maintenance chemotherapy for small-cell lung cancer. A new publication]. Rev Pneumol Clin 2003; 59:179-180. [PMID: 13130207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
|
36
|
Bauduceau O, Ceccaldi B, Bernard O, Dourhte LM, Le Moulec S, Hervé R. [Cylindroma of the trachea, a rate tumor with unusual evolution]. Presse Med 2003; 32:602. [PMID: 12718319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/02/2023] Open
|